Teva UK and Closed Loop Medicine partner to advance development of personalised medicines
Teva UK and Closed Loop Medicines have announced a strategic partnership that aims to advance the development of personalised medicines. The collaboration intends to advance the development of personalised medicines and improve drug efficacy and outcomes in patients with specific chronic disorders.
Chronic conditions, including heart disease, cancer and diabetes, are health conditions or diseases that are persistent or long-lasting in their effects. Most often, existing medicines are typically prescribed based on their average effects in a population and only rarely dose-optimised for the patient, leading to increased side effects and adverse reactions, as well as medication non-adherence, poorer patient outcomes and increased healthcare costs.
In 2016, the annual cost of drug-related morbidity and mortality resulting from non-optimised medication was estimated to cost the US $528.4bn, while the projected annual cost of adverse drug reactions to the UK’s NHS is £2.21bn.
Under the terms of the agreement, Closed Loop Medicine’s proprietary software as a medical device (SaMD) technology platform will be collaboratively used to investigate opportunities to advance personalised medicines and combine dose-optimised drug therapy with digital care to improve drug efficacy and outcomes for patients.
In a recent clinical trial led by researchers at the William Harvey Research Institute at Queen Mary University, called PERSONAL-CovidBP, to evaluate Closed Loop Medicine’s hypertension product, CLM-HT01, the SaMD demonstrated its capability to dose-optimise drug therapy.
Published in the Journal of the American Heart Association, SaMD also minimised side effects while achieving blood pressure control with high medication adherence. The SaMD platform will be used in combination with Teva’s pharmaceutical products to create the opportunity for digital companions to be prescribed alongside traditional therapeutics, to enable real-world data integration and to improve the effectiveness of innovative and known medicines.
“The potential to combine ‘drug’ and ‘digital’ could create significant improvements to [the] lives of patients at great scale,” said Kim Innes, general manager, UK and Ireland, Teva.
Dr Hakim Yadi, chief executive officer and co-founder, Closed Loop Medicine, commented: “This commercial partnership is an example of the potential and scalability of our SaMD technology platform… to improve disease management and patient outcomes at an individual level.”
March 29, 2024
